HOSPITALS

deuruxolitinib has two open-label, longterm extension studies ongoing in North America and Europe in joint efforts to advance the potential treatment of Alopecia Areata, which may affect up to 2.5% of the United States and global population during their lifetime.

With the acquisition of Concert, Sun Pharma seeks to build its global Dermatology and Ophthalmology franchise and aims to be a preferred development and commercial partner in these therapies worldwide. The Indian drug major has agreed to sell a nontradeable contingent value right (CVR) to Concert stockholders entitling holders to an additional US$3.50 per share of common stock in cash as of January 18, 2023.